Didanosine, Lamivudine, and Efavirenz versus Zidovudine, Lamivudine, and Efavirenz for the Initial Treatment of HIV Type 1 Infection: Final Analysis (48 Weeks) of a Prospective, Randomized, Noninferiority Clinical Trial, GESIDA 3903

Background. The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been insufficiently analyzed in clinical trials. Methods. We conducted an open-label, randomized study to compare the noninferiori...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2008-10, Vol.47 (8), p.1083-1092
Main Authors: Berenguer, Juan, González, Juan, Ribera, Esteban, Domingo, Pere, Santos, Jesús, Miralles, Pilar, Angels Ribas, Mª, Asensi, Víctor, Gimeno, Juan Luis, Pérez-Molina, José Antonio, Terrón, José Alberto, Santamaría, Juan Miguel, Pedrol, Enric
Format: Article
Language:English
Subjects:
Adult
AIDS
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - adverse effects
Anti-HIV Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiretroviral drugs
Antiretroviral Therapy, Highly Active
Antiviral agents
Benzoxazines - administration & dosage
Benzoxazines - adverse effects
Benzoxazines - therapeutic use
Biological and medical sciences
CD4 Lymphocyte Count
Clinical trials
Comparative analysis
Didanosine - administration & dosage
Didanosine - adverse effects
Didanosine - therapeutic use
Female
Genetic mutation
HIV
HIV 1
HIV Infections - drug therapy
HIV Infections - virology
HIV-1 - isolation & purification
HIV/AIDS
Hospitals
Human immunodeficiency virus
Human immunodeficiency virus 1
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infections
Infectious diseases
Lamivudine - administration & dosage
Lamivudine - adverse effects
Lamivudine - therapeutic use
Male
Medical sciences
Medications
Middle Aged
Pharmacology. Drug treatments
Prospective Studies
Ribonucleic acid
RNA
RNA, Viral - blood
Severity of Illness Index
Toxicity
Treatment Outcome
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral Load
Virology
Writing tablets
Zidovudine - administration & dosage
Zidovudine - adverse effects
Zidovudine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been insufficiently analyzed in clinical trials. Methods. We conducted an open-label, randomized study to compare the noninferiority of ddI/3TC/EFV with the lamivudine-zidovudine tablet and EFV (COM/EFV), both administered with food to improve tolerability and convenience. Patients were stratified by HIV-1 RNA level of
ISSN:1058-4838
1537-6591
DOI:10.1086/592114